RhoVac receives approval to initiate a long-term follow-up of clinical phase I/II patients
RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today, 9[th] June 2021, that it has received full approvals to initiate a follow-up study of the patients that took part in the company’s clinical phase I/II trial in prostate cancer in Denmark. This trial completed its treatment part in 2018 and a 1-year follow-up period in 2019. The objective of the long-term follow study, to be conducted in the coming months, is to find out to what extent these patients still have the appropriate level of RhoC specific immune response, what their PSA development has been, and to what